AstraZeneca invests $300m to build new facility in US
Pharmaceutical Technology
FEBRUARY 7, 2024
AstraZeneca is investing $300m in a facility in Rockville, US - a significant step in launching its cell therapy platforms in the country.
Sat.Feb 03, 2024 - Fri.Feb 09, 2024
97 
PBMs take bulk of blame as senators question BMS, J&J and Merck CEOs on high drug prices in US
Fierce Pharma
FEBRUARY 8, 2024
Thursday, when senators questioned three Big Pharma CEOs about the high price of drugs in the U.S., Health, Education, Labor and Pensions (HELP) committee chairman Bernie Sanders, I-Vermont, put th | CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Overcoming Hearing Healthcare Barriers to Realize Gene Therapy Promise
MedCity News
FEBRUARY 6, 2024
The preliminary results from three clinical trials administering gene therapy to address deafness from otoferlin mutations mark inspiring and incredible progress in hearing healthcare.
Study reveals AI can predict patients’ survival in glioblastoma
PharmaTimes
FEBRUARY 5, 2024
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Alternative therapies are needed to combat the impending threat of AMR
Pharmaceutical Technology
FEBRUARY 6, 2024
The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024.
AstraZeneca brings its cell therapy ambitions to Maryland with $300M plant investment, 150 planned hires
Fierce Pharma
FEBRUARY 6, 2024
Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. | AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply. In turn, AZ will create more than 150 new jobs.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Drug/software combination improves blood pressure control
pharmaphorum
FEBRUARY 9, 2024
The combination of drugs for hypertension and software to personalise dosing to an individual patient has been shown to deliver improved blood pressure control and adherence to therapy in a pilot study.
Researchers identify new treatment target for genetic epilepsy
PharmaTimes
FEBRUARY 9, 2024
The rare neurodevelopmental condition CDKL5 is characterised by early-onset epilepsy
AstraZeneca hit CEO Pascal Soriot's $45B revenue goal after all. But is Enhertu approaching a plateau?
Fierce Pharma
FEBRUARY 8, 2024
With $45.8 billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. | AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014. But questions have emerged for one of the company's key growth drivers.
Five Ways AI Will Impact Clinical Trials This Year
MedCity News
FEBRUARY 8, 2024
The integration of AI technologies holds promise for enhancing outreach efforts, streamlining recruitment processes, and addressing long-standing barriers and biases that hinder diversity and inclusion in clinical trials.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Gilead drops CD47 drug magrolimab for blood cancers
pharmaphorum
FEBRUARY 8, 2024
Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.
US Senate committee interrogates big pharma on “outrageously high” drug prices
Pharmaceutical Technology
FEBRUARY 9, 2024
Pharma CEOs defended their high prescription drug costs, stating that the current prices are necessary for continued innovation.
As cancer drug shortages persist, ASCO official urges congressional action at hearing
Fierce Pharma
FEBRUARY 9, 2024
A year into a dire shortage of essential cancer medicines in the U.S., the American Society of Clinical Oncologists (ASCO) is again pushing Congress to act to end the crisis. | The oncology drug supply crisis has entered its second year, and doctors still face "impossible choices" without access to standard-of-care therapies, ASCO's chief medical officer, Dr.
Increasing the Impact of Opioid Settlement Funds by Investing in Health IT Infrastructure
MedCity News
FEBRUARY 7, 2024
Strengthening health IT infrastructure is a critical and necessary step toward abating the opioid crisis and evaluating the impact of how opioid settlement dollars are allocated across communities.
Jazz buys KRAS inhibitors from Redx in $880m deal
pharmaphorum
FEBRUARY 7, 2024
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into targeted cancer therapies. Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright, including multiple preclinical-stage drug candidates, and will take responsibility for ushering the most promising compounds through clinical trials and onto the market.
BioNTech agrees collaboration to accelerate autologous CAR-T therapies
European Pharmaceutical Review
FEBRUARY 9, 2024
BioNTech SE and Autolus Therapeutics have agreed to collaborate to advance autologous CAR-T cell therapies. Under the terms of the agreement, BioNTech will pay $50 million to Autolus, granting the immunotherapy company rights including the option to access Autolus’ commercial and clinical site network, manufacturing capacities in the UK and commercial supply infrastructure.
Novo Nordisk settles with 2 Florida sellers of compounded Ozempic
Fierce Pharma
FEBRUARY 9, 2024
Novo Nordisk has reached confidential settlements with two Florida sellers of compounded versions of the mega-blockbuster semaglutide treatments Ozempic and Wegovy, the company said on Friday. | Novo Nordisk has reached confidential settlements with two Florida sellers of compounded versions of the mega-blockbuster semaglutide treatments Ozempic and Wegovy, the company said on Friday.
We’ll See More Exits & Reduced Valuations Among Digital Health Startups This Year, Experts Say
MedCity News
FEBRUARY 5, 2024
This year, industry experts think that some digital health startups will have to confront their challenges more head-on than they did in 2023. Some companies may need to do things like fundraise at a lower valuation, explore opportunities for an acquisition or exit or, in some cases, consider the possibility of shutting down operations.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
More pharma M&A as Novartis snaps up MorphoSys for $2.9bn
pharmaphorum
FEBRUARY 6, 2024
Novartis has agreed to buy Germany's MorphoSys in a transaction that values the cancer-focused biotech at $2.
Study reveals blood test can pinpoint cause of brain injury in newborns
PharmaTimes
FEBRUARY 6, 2024
Hypoxic-ischaemic encephalopathy affects around three million babies worldwide every year
Eli Lilly mounts clinical and commercial case for tirzepatide as Mounjaro, Zepbound chalk up major gains
Fierce Pharma
FEBRUARY 6, 2024
Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP | Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity.
Tech-Enabled Biology: Pioneering a New Era in Biotechnology
MedCity News
FEBRUARY 9, 2024
The new era of full-stack compute-enabled bio companies will drive incredible advances in human health.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Could the next Alzheimer’s drug discovery be… Viagra?
pharmaphorum
FEBRUARY 8, 2024
Epidemiological studies can often throw out intriguing and sometimes erroneous correlations between a variable and a disease, but UK scientists say a finding that Alzheimer’s disease seems to be less common in Viagra users warrants further investigation.
What Goes into Planning LogiPharma Europe?
Pharmaceutical Commerce
FEBRUARY 9, 2024
A dive into the intricacies of how to ensure a long-running event stays fresh and relevant to the needs of the pharmaceutical industry.
Novartis CEO’s 2023 pay rises 21% as Roche's helmsman nets $11M in his first year
Fierce Pharma
FEBRUARY 5, 2024
After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. | After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.
Using Technology To Navigate the Care Journey
MedCity News
FEBRUARY 5, 2024
The only way to effectively scale care coordination to meet the needs of digital consumers is through technology, combined with empowered staff and transformed processes.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Astellas raises Padcev forecasts on bladder cancer data
pharmaphorum
FEBRUARY 5, 2024
A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.
RegenxBio advances two candidates to make waves in the CNS space
Pharmaceutical Technology
FEBRUARY 8, 2024
AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards an FDA BLA.
GSK details Blenrep combo data that could bring the multiple myeloma ADC back to life
Fierce Pharma
FEBRUARY 5, 2024
If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. | If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep.
Novo Holdings Bolsters GLP-1 Production Capacity With $16.5B Catalent Buyout
MedCity News
FEBRUARY 5, 2024
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.
Let's personalize your content